MEI, Infinity report all-stock transaction to advance three oncology candidates MEIPINFI
| MEIP Stock | USD 2.77 0.06 2.12% |
Slightly above 62% of MEI Pharma's investor base is looking to short. The analysis of overall sentiment of trading MEI Pharma stock suggests that many investors are alarmed at this time. MEI Pharma's investing sentiment overview a quick insight into current market opportunities from investing in MEI Pharma. Many technical investors use MEI Pharma stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
MEI |
MEI Pharma and Inf... MEIP, INFI
Read at thefly.com
 |
MEI Pharma Fundamental Analysis
We analyze MEI Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of MEI Pharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of MEI Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Current Valuation
Current Valuation Comparative Analysis
MEI Pharma is currently under evaluation in current valuation category among its peers. Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
MEI Pharma Potential Pair-trading
One of the popular trading techniques among algorithmic traders is to use market-neutral strategies where every trade hedges away some risk. Because there are two separate transactions required, even if one position performs unexpectedly, the other equity can make up some of the losses. Below are some of the equities that can be combined with MEI Pharma stock to make a market-neutral strategy. Peer analysis of MEI Pharma could also be used in its relative valuation, which is a method of valuing MEI Pharma by comparing valuation metrics with similar companies.
Peers
MEI Pharma Related Equities
| ABOS | Acumen Pharmaceuticals | 7.36 | ||||
| TERN | Terns Pharmaceuticals | 4.94 | ||||
| ASMB | Assembly Biosciences | 4.55 | ||||
| DAWN | Day One | 1.14 | ||||
| ZURA | Zura Bio | 1.13 | ||||
| KZR | Kezar Life | 1.11 | ||||
| ACHL | Achilles Therapeutics | 0.88 | ||||
| TIL | Instil Bio | 0.56 | ||||
| RNAZ | Transcode Therapeutics | 0.85 | ||||
| OCUL | Ocular Therapeutix | 1.24 | ||||
| HOOK | Hookipa Pharma | 2.45 | ||||
| SPRO | Spero Therapeutics | 3.33 | ||||
| CTMX | CytomX Therapeutics | 3.45 | ||||
| INZY | Inozyme Pharma | 3.70 | ||||
| ZVSA | ZyVersa Therapeutics | 5.41 | ||||
| ATXI | Avenue Therapeutics | 6.49 | ||||
| PHIO | Phio Pharmaceuticals | 7.66 | ||||
| REVB | Revelation Biosciences | 14.63 | ||||
| VINC | Vincerx Pharma | 26.67 |
Additional Tools for MEI Stock Analysis
When running MEI Pharma's price analysis, check to measure MEI Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy MEI Pharma is operating at the current time. Most of MEI Pharma's value examination focuses on studying past and present price action to predict the probability of MEI Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move MEI Pharma's price. Additionally, you may evaluate how the addition of MEI Pharma to your portfolios can decrease your overall portfolio volatility.